BDRX logo

BDRXBiodexa Pharmaceuticals Plc

$3.01
$0.09
(2.90%)
Today
Closed $3.01
$0.01
(0.33%)
After Hours
Updated: 06:15 PM EDT
Mkt Cap$1.36M
Vol17,731.00
News
all
press releases
Insider Signals and Potential Moonshots that Could Reset Valuations
Biotech and pharma markets are leading the way in a sharply selective environment at midday, where clinical data, insider conviction, and platform scalability are driving outsized moves while weaker narratives get left behind. $NTHI, $POET, $SDOT, $BDRX, $CLRB, $DOCN, $FSLY, $EWTX, $BLDP
24-7 Market News
News Placeholder
More News
News Placeholder
Why Is Biodexa Pharmaceuticals (BDRX) Stock Skyrocketing Today?
Biodexa Pharmaceuticals shares are trading sharply higher Thursday afternoon after the company said it partnered with Syngene International.read more...
Benzinga
News Placeholder
Biodexa Pharmaceuticals Stock Surges 69% Over Partnership With Syngene International
(RTTNews) - Shares of Biodexa Pharmaceuticals Plc (BDRX) are climbing about 69 percent on Thursday morning trading after it announced a partnership with Syngene International Ltd for the manufacture...
Nasdaq News: Markets
News Placeholder
Energy Crunch Sparks Sector Rally and Hidden Players Stepping into the Spotlight
A powerful convergence of global energy disruption and emerging technology catalysts is reshaping pockets of the market, with select small-cap names ready to make moves. $SKYQ, $XERI, $KBLB, $TGNT, $BDRX, $COCP
24-7 Market News
News Placeholder
Biodexa Promotes Fiona Sharp To CFO As Stephen Stamp Cedes Role To Become Only CEO
(RTTNews) - Biodexa Pharmaceuticals Plc (BDRX), a clinical stage biopharmaceutical company, Monday announced that it has promoted Fiona Sharp to Chief Financial Officer and Company Secretary...
Nasdaq News: Markets
News Placeholder
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Upgraded to Buy: What Does It Mean for the Stock?
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks
News Placeholder
Biodexa Stock Surges On FDA's Fast-Track Tag For Treatment Of Cancer-Causing Condition: Retail Confidence Peaks
The drug, a proprietary encapsulated form of rapamycin, is being developed for familial adenomatous polyposis (FAP), a condition that, if left untreated, universally leads to colorectal cancer.
Stocktwits
<
...
1
>

Advertisement|Remove ads.